WALTHAM, Mass. - Monday, November 5th 2012 [ME NewsWire]
(BUSINESS WIRE)-- PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced the launch of a panel of nine new epigenetic research assay kitsfor the detection of endogenous histone modifications at the Revolutionaries for Global Health Summit (RGH), a global scientific community event dedicated to advancing personalized health. Last week’s RGH Summit in San Francisco, is part of a global series hosted by PerkinElmer to share advanced research and foster collaboration among researchers and practitioners as they deploy PerkinElmer’s disruptive technologies and approaches to support research to prevent, detect, and treat disease.
"PerkinElmer is dedicated to providing a forum for revolutionary change in the way we approach research, and ultimately, healthcare,” said Kevin Hrusovsky, president Life Sciences and Technology, PerkinElmer. "Through our Revolutionaries for Global Health Summits that are held across the globe, we are facilitating a cross-functional effort to advance research by bringing together leaders in academia, government and commercial enterprise, in the hopes of one day eradicating cancer and other diseases. I am very excited about our new epigenetic panel launched at last week’s Summit, which will play a vital role in helping researchers to uncover treatments that reverse environmental causes of disease.”
Designed for high throughput screening of targets related to writers and erasers of the histone code, these new novel Alpha technology-based reagents are the only homogenous cellular assays for endogeneous histone modification research. Because cell-based assays are closely related to true biology, researchers are able to obtain more robust, physiologically relevant results than traditional Western Blot or ELISA methods. The new assay kits complement a portfolio of both cellular and biochemical assays that offer a faster, more efficient path to the identification of treatments for epigenetic-related disease states.
In addition to the newly launched epigenetics panel, PerkinElmer also highlighted several new product introductions at the RGH event, including:
Spotfire® data visualization toolsfor discovering novel insights from big data experiments,
Enhancements to ChemBioOffice, a software productivity suite with over one million users, and
JANUS® Laboratory automation workstationsfor next generation sequencing and biotherapeutics sample preparation.
The Revolutionaries for Global Health Summit unites a community of people with diverse backgrounds to advance personalized health. The focus of the summit is uncovering better approaches for disease control and prevention; identifying appropriate tools to develop new diagnostics and screening tools for early stage detection and predisposition of disease and developing safer and more effective personalized therapeutics. The global events have attracted over 3,000 scientists and 300 speakers in the past 12 months. Presentations from recent events are available online at www.perkinelmer.com/rghs.
About PerkinElmer, Inc.PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Contacts
Edelman (On behalf of PerkinElmer, Inc.)
Paul Barren, 404-460-9679
paul.barren@edelman.com
|
